As understanding of the structure and function of the epidermal barrier has improved over the past several years, treatment strategies for various dermatologic conditions have changed to incorporate barrier support and repair. Barrier support is now commonly used for atopic dermatitis,1,2 as well as for other inflammatory diseases of the skin such as psoriasis, acne, and rosacea. The market for epidermal barrier repair formulations is large, and it includes both prescription and over-the-counter (OTC) options. The cost of these formulations varies widely and, because of their approval status as a medical device rather than a drug, some third-party payers unfortunately may not cover prescription barrier therapies, thus limiting their use.
Cetaphil® Restoraderm® Moisturizer (Galderma Laboratories, L.P.; Fort Worth, TX) and its associated Body Wash from Galderma are a welcome OTC option for atopic dermatitis patients. Restoraderm Body Wash and Moisturizer are specifically created to address the needs of atopic dermatitis patients, both adult and pediatric. Of note, the Restoraderm product line is formulated with advanced ceramide technology and filaggrin breakdown products to support the natural components of the epidermal barrier.
Cetaphil Restoraderm products are widely available and competitively priced, making them accessible to a large majority of the patient population.
The emerging and available data on epidermal barrier function and its repair confirm that barrier support is a crucial element in treating patients with atopic dermatitis and several other common dermatoses. As discussed in the pages ahead, the Restoraderm Body Wash and Moisturizer product line has extensive clinical data to support its positive effect on the epidermal barrier system in atopic patients.
Leon H. Kircik MD
Mount Sinai Medical Center, New York, NY Indiana University School of Medicine, Indianapolis, IN Physicians Skin Care, PLLC, Louisville, KY
Indiana University School of Medicine, Indianapolis, IN
Dr. Kircik has received compensation from the Journal of Drugs in Dermatology for his editorial support.
References
- Wollenberg A, Schnopp C. Evolution of conventional therapy in atopic dermatitis. Immunol Allergy Clin North Am. 2010;30(3):351-368.
- Elias PM, Wakefield JS. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis. Clin Rev Allergy Immunol. 2011;41(3):282-295.
